Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03541174 · ClinicalTrials.gov registry record · Phase 3
A Research Study to Show the Effect of Aprocitentan in the Treatment of Difficult to Control (Resistant) High Blood Pressure (Hypertension) and Find Out More About Its Safety
A Phase 3 study, sponsored by Idorsia Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 730
- Enrollment target
NCT03541174 is a Phase 3 study that has completed, run by Idorsia Pharmaceuticals. The registered enrollment target is 730 participants.
The verdict
NCT03541174, a Phase 3 study, has completed, sponsored by Idorsia Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 730 participants
- Enrollment target
Study Summary
The goal of this clinical trial is to show the blood pressure lowering effect of aprocitentan, a new drug, when added to other anti-hypertensive drugs of patients with difficult to control (resistant) high blood pressure (hypertension), and to show that blood pressure reduction is kept for long period of time.
Interventions
- DRUG Placebo
- DRUG Aprocitentan 25 mg
- DRUG Aprocitentan 12.5 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 730 participants |
| Start Date | 2018-06-18 |
| Est. Completion | 2022-04-25 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03541174
The ClinicalTrials.gov registry entry for NCT03541174 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 730 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Idorsia Pharmaceuticals, which has 34 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT03541174 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03541174 about?
NCT03541174 is a clinical study titled "A Research Study to Show the Effect of Aprocitentan in the Treatment of Difficult to Control (Resistant) High Blood Pressure (Hypertension) and Find Out More About Its Safety". The goal of this clinical trial is to show the blood pressure lowering effect of aprocitentan, a new drug, when added to other anti-hypertensive drugs of patients with difficult to control (resistant) high blood pressure (hypertension), and to show that blood pressure reduction is kept for long peri...
What is the current status of trial NCT03541174?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 730 participants. The study started on 2018-06-18. Estimated completion is 2022-04-25.
What interventions are being tested in trial NCT03541174?
The interventions under investigation include: Placebo (DRUG), Aprocitentan 25 mg (DRUG), Aprocitentan 12.5 mg (DRUG).
Who is sponsoring clinical trial NCT03541174?
This trial is sponsored by Idorsia Pharmaceuticals, which has 34 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.